LAM-003, a new drug for treatment of tyrosine kinase inhibitor–resistant FLT3-ITD–positive AML

Acute myeloid leukemias (AML) harboring a constitutively active internal tandem duplication (ITD) mutation in the FMS-like kinase tyrosine kinase (FLT3) receptor are associated with poor patient prognosis. Despite initial clinical responses to FLT3 kinase inhibitors, patients eventually relapse. Mec...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Blood Adv
Autors principals: Beeharry, Neil, Landrette, Sean, Gayle, Sophia, Hernandez, Marylens, Grotzke, Jeff E., Young, Peter R., Beckett, Paul, Zhang, Xuan, Carter, Bing Z., Andreeff, Michael, Halene, Stephanie, Xu, Tian, Rothberg, Jonathan, Lichenstein, Henri
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2019
Matèries:
Myeloid Neoplasia
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6880894/
https://ncbi.nlm.nih.gov/pubmed/31751472
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019001068
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars